Utility of haemostatic markers to identify patients with an acute coronary syndrome (ACS) or specifically evolving a cTnT positive ACS
| Haemostatic marker cut off | Area under the ROC curve | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
| Data presented with 95% confidence intervals. | |||||
| cTnT; cardiac troponin T; F1+2, prothrombin fragment 1+2; NPV, negative predictive value; PAI, plasminogen activator inhibitor; PPV, positive predictive value; ROC, receiver operating characteristic; TAT, thrombin-antithrombin; TFPI, tissue factor pathway inhibitor. | |||||
| Detecting ACS at large | |||||
| F1+2 >1.1 nmol/l | 0.53 (0.44 to 0.63) | 31 (22 to 40) | 80 (70 to 90) | 71 (57 to 85) | 42 (33 to 51) |
| TAT complexes >6.0 ng/ml | 0.52 (0.42 to 0.61) | 27 (18 to 36) | 80 (70 to 90) | 68 (53 to 83) | 40 (31 to 49) |
| TFPI activity >1400 U/l | 0.57 (0.48 to 0.66) | 29 (20 to 38) | 79 (69 to 89) | 68 (54 to 82) | 40 (33 to 51) |
| PAI >110 ng/ml | 0.61 (0.52 to 0.70) | 28 (19 to 37) | 85 (76 to 94) | 75 (61 to 89) | 43 (34 to 52) |
| Detecting cTnT positive ACS (case group 2) | |||||
| F1+2 >1.1 nmol/l | 0.62 (0.53 to 0.71) | 40 (28 to 52) | 83 (75 to 91) | 62 (47 to 77) | 66 (57 to 75) |
| TAT complexes >6.0 ng/ml | 0.59 (0.50 to 0.68) | 29 (18 to 40) | 79 (71 to 87) | 50 (34 to 66) | 61 (52 to 70) |
| TFPI activity >1400 U/l | 0.55 (0.46 to 0.64) | 28 (17 to 39) | 76 (67 to 85) | 44 (29 to 59) | 60 (51 to 69) |
| PAI >95 ng/ml | 0.54 (0.45 to 0.63) | 29 (18 to 40) | 76 (67 to 85) | 45 (30 to 60) | 61 (52 to 70 |